Background Previous real-world studies of first-line (1L) atezolizumab+carboplatin+etoposide for ES-SCLC in the US community oncology setting showed similar treatment durations (medians: 4.9;5.7 months) as in the IMpower133 trial (median: 4.7 months) although the real-world populations had higher proportions of patients with poor ECOG performance status (PS) and brain metastases.1,2 This study measured treatment duration in an older ES-SCLC population initiating 1L atezolizumab+carboplatin+etoposide and the impact of ECOG PS and brain metastases at baseline on treatment duration.
Methods This retrospective cohort study utilized the 100% sample of Medicare Fee-For-Service enrollment and Parts A/B claims from January 1, 2018 to June 30, 2021. Beneficiaries with ≥2 claims with an ICD-10-CM code for lung cancer and claims for atezolizumab+carboplatin+etoposide were identified. Index was 1L treatment initiation occurring between October 11, 2018 to December 31, 2019. ECOG PS at baseline was approximated using a claims-based measure that classifies individuals as good (ECOG 0-1) or fair/poor (ECOG≥2) based on healthcare utilization in the 12-month pre-index period.3 Baseline brain metastases were identified from diagnosis to 30 days post-index based on ICD-10-CM codes. 1L treatment duration was measured from index to a gap in treatment claims of ≥60 days, initiation of a new anti-cancer regimen or death. Kaplan-Meier curves were utilized to examine the differences for patients stratified by brain metastases (Y/N) and binary ECOG PS.
Results A total of 2,470 patients older than 65 years (median age: 73 years) were included in the study with a median follow-up of 8.4 months. 62% had a proxy for fair/poor ECOG PS and 22% had baseline brain metastases. Median 1L duration for the full cohort was 5.4 months (95% CI: 5.2-5.6). Median 1L treatment duration was 5.1 months for patients with poor/fair ECOG PS (95% CI: 5.1-5.3) and 5.8 months (95% CI: 5.6-6.0) for patients with good ECOG PS (figure 1) (Log-Rank p<0.0001). Median 1L treatment duration for patients with brain metastases was 5.0 months (95% CI: 4.6-5.3) and 5.5 months (95% CI: 5.3-5.7) for patients without brain metastases (figure 2) (Log-Rank p=0.2488).
Conclusions Despite the older age of the study population and the worse baseline ECOG PS and brain metastases status, 1L treatment duration with atezolizumab+carboplatin+etoposide was similar to those observed in IMpower133 and in previous real-world community oncology studies. Based on descriptive comparisons, treatment duration was longer in patients with a proxy for good ECOG PS (statistically significant) and patients without brain metastases (not statistically significant).
Acknowledgements Shambhavi Kumar for statistical analysis.
Nadler, Eric S, et al. Real-world evidence of cancer immunotherapy (CIT) combination treatment in first-line (1L) extensive-stage small cell lung cancer (ES-SCLC). 2021;8561–8561.
Tsui DCC, et al. 1650P Adoption and early clinical outcomes of atezolizumab (atezo)+ carboplatin and etoposide (CE) in patients with extensive-stage small cell lung cancer (ES-SCLC) in the real-world (RW) setting. Annals of Oncology. 2021;32:S1164.
Sheffield, Kristin M, et al. Development and validation of a claims-based approach to proxy ECOG performance status across ten tumor groups. Journal of Comparative Effectiveness Research. 2018;7(3):193–208.
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.